TauroPharm

What TauroPharm does

TauroPharm GmbH is a German specialty medical-device manufacturer headquartered in Waldbüttelbrunn, Germany. Founded with the commercial tagline 'Saving lives with locked lines since 2004,' the company develops and markets antimicrobial catheter lock solutions for central-venous access systems used in dialysis, oncology, parenteral nutrition, and intensive care. Its product platform is built on taurolidine, an antimicrobial agent that provides antibacterial, antibiofilm, and antiocclusive activity when instilled into catheters between treatment sessions.

The portfolio comprises five core SKUs and one branded protocol: TauroLock™ (general-purpose antimicrobial lock), TauroLock™-HEP100 (heparin-compatible variant for patients previously on heparin locks), TauroLock™-HEP500 (dialysis-specific formulation), TauroLock™-U25.000 (taurolidine combined with 4% citrate and 25,000 IU urokinase for high-protection use), NutriLock™ (heparin- and citrate-free taurolidine lock for parenteral nutrition), and the 2+1 dialysis protocol (2x weekly TauroLock™-HEP500 plus 1x weekly TauroLock™-U25.000). Manufacturing and distribution operate under ISO 13485 medical-device quality certification. Trademarks TauroLock™ and NutriLock™ are registered.

TauroPharm runs a direct B2B sales motion targeting hospitals, dialysis centers, oncology departments, and intensive care units, with contact-based pricing and no publicly disclosed price points. Distribution is global in scope, evidenced by a website available in nine languages (English, German, French, Bulgarian, Romanian, Portuguese, Russian, Spanish, Italian) and active participation in international medical congresses such as ESPEN. The company is privately held with 11–50 employees, no disclosed funding rounds, no disclosed M&A activity, and no disclosed management team in the source data. Revenue is not publicly disclosed.

Note: there is a date discrepancy in the input — the firmographics block lists year_founded 1999, while the company-history block and the company's own website material give a founded/operating-since date of 2004; per source-precedence rules the first-party 2004 date is used here.

Name

TauroPharm

Legal name

TauroPharm GmbH

Website

https://taurolock.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

TauroPharm GmbH is a German specialty medical-device manufacturer that develops and sells taurolidine-based antimicrobial catheter lock solutions (TauroLock™ and NutriLock™ lines) to hospitals, dialysis centers, oncology departments, and intensive care units across Europe and other international markets.

Ownership category

akta.pro rank

Product category

Antimicrobial Catheter Lock Solutions

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIAAAG

Infectious Disease & Antimicrobials Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Antimicrobial lock solutions
• Catheter lock solutions
• Dialysis pharmaceuticals
• Parenteral nutrition products
• Oncology catheter care

Headquarters

HQ city

Waldbüttelbrunn

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device/Pharmaceutical Product Sales: TauroPharm generates revenue through the sale of proprietary catheter lock solutions to healthcare institutions. The product portfolio includes multiple formulations (TauroLock™, TauroLock™-HEP100, TauroLock™-HEP500, TauroLock™-U25.000, NutriLock™) targeting different patient populations and clinical applications in dialysis, oncology, parenteral nutrition, and intensive care settings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

TauroPharm manufactures and sells proprietary taurolidine-based antimicrobial catheter lock solutions designed to prevent catheter-related bloodstream infections, occlusions, and biofilm formation in central-venous access systems. The portfolio includes multiple formulations (TauroLock™, TauroLock™-HEP100, TauroLock™-HEP500, TauroLock™-U25.000, NutriLock™) tailored for use in dialysis, oncology, parenteral nutrition, and intensive care settings. The company sells directly to healthcare institutions including hospitals, dialysis centers, oncology departments, and ICUs.

Product overview

TauroPharm is a pharmaceutical company specializing in antimicrobial catheter lock solutions for central-venous access systems. The product portfolio is a multi-product line built around taurolidine-based technology, with distinct formulations targeting different patient needs. The core offerings include TauroLock™ (general-purpose antimicrobial lock), TauroLock™-HEP100 (heparin-compatible variant), TauroLock™-HEP500 (dialysis-specific formulation), TauroLock™-U25.000 (high-dose urokinase variant), and NutriLock™ (heparin/citrate-free alternative). These lock solutions combine antimicrobial, antiocclusive, and antibiofilm efficacy to prevent catheter-related complications. Additionally, TauroPharm offers the 2+1 protocol as a structured treatment regimen for dialysis patients. The company has been operating since 2004.

Differentiator

Problem solved

Functional benefit

Brands

• TauroLock™: Primary product line of antimicrobial lock solutions for instillation in central-venous access systems. Prevents formation of bacterial biofilms and improves patency rate.
• TauroLock™-HEP100
• TauroLock™-HEP500
• TauroLock™-U25.000
• NutriLock™

Products and services

• TauroLock™ Antimicrobial lock solution recommended for instillation in all central-venous access systems. Prevents the formation of bacterial biofilms and improves catheter patency rate. Sold to hospitals, dialysis centers, oncology departments, and ICUs.
• TauroLock™-HEP100 Lock solution containing taurolidine and heparin (100 IU) for patients previously on heparin-based lock solutions. Maintains central-venous catheters infection-free with high patency rate.
• TauroLock™-HEP500 Lock solution developed specifically for dialysis patients, containing taurolidine and 500 IU heparin. Prevents catheter-related infections and occlusions while ensuring good flow-rate.
• TauroLock™-U25.000 Lock solution providing strong protection against catheter-related complications. Contains taurolidine, 4% citrate, and 25,000 IU urokinase. Particularly strong protection against catheter occlusions and infections.
• NutriLock™ Heparin-free and citrate-free lock solution based on the antimicrobial agent taurolidine. Protects patients against catheter-related infections, specifically designed for parenteral nutrition applications.
• 2+1 Protocol Treatment protocol for dialysis patients combining TauroLock™-HEP500 (2x weekly) and TauroLock™-U25.000 (1x weekly) to comprehensively prevent catheter-related infections and occlusions in dialysis catheter maintenance.

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• CorMedix: CorMedix develops DefenCath, a taurolidine-based antimicrobial catheter lock solution approved for hemodialysis patients — the closest direct competitor to TauroPharm's TauroLock™ portfolio, competing on the same mechanism of action and same clinical use case.
• Fresenius Medical Care: The world's largest provider of dialysis products and services, Fresenius Medical Care is both a major channel for catheter maintenance solutions in dialysis and a potential competitor/partner, with direct overlap in the dialysis catheter patient population that is TauroPharm's core segment.
• Medcomp: Medcomp is a manufacturer of central venous catheters and vascular access devices, including dialysis catheters, directly overlapping with TauroPharm in the central venous catheter ecosystem targeted by TauroLock™ lock solutions.

Broad incumbents

• Becton Dickinson (BD): BD is a global medical device leader with an extensive vascular access portfolio including central venous catheters and related catheter maintenance products, making it a broad incumbent competitor in the same end-customer environment as TauroPharm.
• Baxter International: Baxter manufactures parenteral nutrition products, dialysis solutions, and IV therapy equipment, serving the same hospital customers and overlapping with TauroPharm in the parenteral nutrition catheter lock segment (NutriLock™).
• ICU Medical: ICU Medical produces IV therapy, critical care, and vascular access products including needlefree connectors and catheter-related disposables, competing in adjacent catheter care categories within the same hospital customer base.
• Teleflex: Teleflex manufactures a broad portfolio of vascular access devices and central venous catheters used in the same hospital and dialysis environments where TauroPharm's lock solutions are deployed, representing a wider incumbent with overlapping customer base.
• B. Braun: B. Braun is a major German-headquartered medical device and pharmaceutical company with extensive parenteral nutrition, IV therapy, and dialysis product portfolios, serving as a broader incumbent competitor in the same institutional healthcare customers as TauroPharm.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tauropharm-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TauroPharm